DiaMedica Therapeutics (DMAC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapies for preeclampsia (PE) and acute ischemic stroke (AIS), with lead candidate DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 (KLK1) protein in clinical development for both indications.

• DM199 is the first and only recombinant KLK1 in global clinical trials for PE and AIS, with Fast Track designation from the FDA for AIS.

• Pipeline includes DM199 for PE and AIS, and DM300, a preclinical candidate for severe acute pancreatitis.

Financial performance and metrics

• Recent private placement in July 2025 raised gross proceeds of approximately $30.1 million through the sale of 8,606,425 common shares at $3.50 per share.

• As of July 23, 2025, 51,688,913 common shares were outstanding, with additional shares reserved for options and incentive plans.

Use of proceeds and capital allocation

• Net proceeds from the July 2025 private placement are intended for continued clinical and product development activities for DM199 and for general corporate purposes.

• No proceeds will be received from the resale of shares by selling shareholders under this registration; the company will bear related registration expenses.